What would happen if the level of rankl increased

RANKL binds to RANK on the surface of osteoclast precursors and recruits the adapter protein, TRAP6, leading to activation of NF-κB through phosphorylation and inactivation of inhibitory kappa kinases (IKKs) and NF-κB inhibitory kinase (not shown here). This induces activation of c-Fos.

What happens when RANKL binds to RANK?

RANKL binds to RANK on the surface of osteoclast precursors and recruits the adapter protein, TRAP6, leading to activation of NF-κB through phosphorylation and inactivation of inhibitory kappa kinases (IKKs) and NF-κB inhibitory kinase (not shown here). This induces activation of c-Fos.

What increases RANKL expression in osteoblasts?

Receptor Activator of Nuclear κ B ligand (RANKL) In breast tumor induced osteolysis, studies have shown that tumor derived PTHrP can stimulate RANKL expression in osteoblasts and that the presence of RANKL on the osteoblast cell surface drives osteoclast maturation (Mundy, 2002).

What is the role of RANKL?

RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Overproduction of RANKL is implicated in a variety of degenerative bone diseases, such as rheumatoid arthritis and psoriatic arthritis.

What is RANKL in osteoporosis?

The interaction of RANK with its ligand (RANKL) has been identified as the final common pathway through which bone resorption is regulated [29]. By binding to its receptor RANK on osteoclastic precursors, RANKL controls the differentiation, proliferation, and survival of osteoclasts.

What is the role of RANK RANKL and OPG in bone formation?

RANKL/RANK signaling regulates osteoclast formation, activation and survival in normal bone modeling and remodeling and in a variety of pathologic conditions characterized by increased bone turnover. OPG protects bone from excessive resorption by binding to RANKL and preventing it from binding to RANK.

What is the interaction between RANK and RANK important for?

The high-affinity interaction between RANK and RANKL, maintained by continuous contact between the pair rather than the patched interaction commonly observed, is necessary for the function because a slightly reduced affinity induced by mutation produces significant disruption of osteoclast formation.

What is RANKL inhibitor?

RANKL inhibitors are used to treat osteoporosis, breast cancer, lung cancer, and prostate cancer. They work by preventing bone fractures and by destroying cancer cells.

What role does estrogen play in bone remodeling?

Estrogen is critical for skeletal homeostasis and regulates bone remodeling, in part, by modulating the expression of receptor activator of NF-κB ligand (RANKL), an essential cytokine for bone resorption by osteoclasts.

Do osteoblasts produce RANKL?

RANKL is expressed on osteoblasts and T cells. It binds the receptor RANK, which is produced on osteoclasts and their progenitors. The interaction of RANK with RANKL is required for osteoclast formation, differentiation, activation and survival.

Article first time published on

What stimulates rankl expression?

Parathyroid hormone (PTH) stimulates osteoclast formation by binding to its receptor on stromal/osteoblastic cells and stimulating the production of receptor activator of NFkappaB ligand (RANKL) and inhibiting the expression of osteoprotegerin (OPG).

What stimulates OPG?

Estrogen stimulates OPG expression mainly at a transcriptional level through the estrogen receptor (ER), particularly ERα (13–15,18). Furthermore, an estrogen response element has been identified in the OPG promoter (19).

What is rankl rank OPG pathway?

The RANK/RANKL/OPG Pathway. The RANKL/RANK/OPG system is known for its roles in osteoclasts maturation, bone modeling, and bone remodeling. Receptor activator of NF-kB (RANK), receptor activator of NF-kB ligand (RANKL), and osteoprotegerin (OPG) are the main components of this signaling system.

How does rankl cause osteoporosis?

It is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, which binds to and inhibits osteoblast-produced RANKL, in turn reduces the binding between RANKL and osteoclast receptor RANK, therefore decreases osteoclast-mediated bone resorption and turnover.

How does estrogen affect osteoporosis?

Menopause predisposes women to osteoporosis due to declining estrogen levels. This results in a decrease in bone mineral density (BMD) and an increase in fractures.

When is peak bone mass attained?

Up to 90 percent of peak bone mass is acquired by age 18 in girls and by age 20 in boys, which makes youth the best time to “invest” in one’s bone health. The amount of bone tissue in the skeleton, known as bone mass, can keep growing until the late 20s.

Does OPG inhibit RANKL?

The RANKL/RANK/OPG system was first identified in the late-1990s as a pivotal regulator of bone remodeling [1,2,3]. … Hence, OPG prevents RANKL from binding to its receptor RANK, inhibiting osteoclastogenesis and protecting the bone from excessive osteoclast-mediated resorption [11, 12].

What roles do glucocorticoids play in bone remodeling RANK RANKL OPG?

Glucocorticoids cause profound effects on bone cell replication, differentiation, and function. Glucocorticoids increase bone resorption by stimulating osteoclastogenesis by increasing the expression of RANK ligand and decreasing the expression of its decoy receptor, osteoprotegerin.

What is the role of osteoprotegerin?

Osteoprotegerin (OPG) is an antiresorptive cytokine and a potential mechanism for immunosuppressant osteopenia. A member of the tumor necrosis factor–receptor superfamily, OPG is a critical regulator of bone resorption. OPG inhibits terminal differentiation and activation of osteoclasts.

What is responsible for Appositional growth?

Appositional growth is the increase in the diameter of bones by the addition of bony tissue at the surface of bones. Osteoblasts at the bone surface secrete bone matrix, and osteoclasts on the inner surface break down bone. The osteoblasts differentiate into osteocytes.

Does OPG bind to RANK or RANKL?

Osteoprotegerin (OPG) is secreted by osteoblasts and osteogenic stromal stem cells and protects the skeleton from excessive bone resorption by binding to RANKL and preventing it from interacting with RANK. The RANKL/OPG ratio in bone marrow is thus an important determinant of bone mass in normal and disease states.

What causes female estrogen?

The ovaries, which produce a woman’s eggs, are the main source of estrogen from your body. Your adrenal glands, located at the top of each kidney, make small amounts of this hormone, so does fat tissue. Estrogen moves through your blood and acts everywhere in your body.

How does estrogen influence bone growth?

During bone growth estrogen is needed for proper closure of epiphyseal growth plates both in females and in males. Also in young skeleton estrogen deficiency leads to increased osteoclast formation and enhanced bone resorption. In menopause estrogen deficiency induces cancellous as well as cortical bone loss.

How does growth hormone estrogen and testosterone affect bone growth?

Sex hormones (estrogen made in the ovary of females and testosterone made by the testes in males) control ability to reproduce. They also are a major reason that bone strength increases in the early teenage years. When teenagers have low estrogen or testosterone levels, the bone becomes weaker.

How do rankl inhibitors work?

It is a receptor activator of nuclear factor-κB ligand (RANKL) inhibitor, which binds to and inhibits osteoblast-produced RANKL, in turn reduces the binding between RANKL and osteoclast receptor RANK, therefore decreases osteoclast-mediated bone resorption and turnover.

What do monoclonal antibodies do for osteoporosis?

Monoclonal antibodies such as denosumab (Prolia) inhibit osteoclast formation, decrease bone resorption, increase BMD, and reduce the risk of fracture.

Does denosumab affect the immune system?

Denosumab is an antibody-based medication, but it doesn’t suppress your immune system. This means it doesn’t increase your risk of complications from the coronavirus. This is unlike other antibody-based medications used to treat diseases like rheumatoid arthritis.

Who produces rankl?

In this context, RANKL that mediate osteoclastogenesis is produced by the synovial fibroblasts under inflammation, as well as T helper 17 (TH17) cells, especially those that with a history of Foxp3 expression (exFoxp3 TH17 cells) (Fig. 1c) [48,49,50].

What stimulates bone resorption?

Hormones play a role in determining when bones go through resorption or formation. These include parathyroid hormone (PTH) and calcitonin. When the level of calcium in the blood is low, the parathyroid activates to release PTH which stimulates osteoclasts to remove bone, thus releasing calcium into the bloodstream.

Do osteocytes produce rankl?

Osteocytes also produce RANKL and OPG, critical regulators of osteoclastogenesis. While osteoblasts and other bone-residing immune cells also produce RANKL, it is now appreciated that RANKL synthesized by osteocytes is a significant source of RANKL driving osteoclast formation for bone remodeling (45–47).

What causes osteopetrosis?

The X-linked type of osteopetrosis, OL-EDA-ID, results from mutations in the IKBKG gene. In about 30 percent of all cases of osteopetrosis, the cause of the condition is unknown. The genes associated with osteopetrosis are involved in the formation, development, and function of specialized cells called osteoclasts.